Post

New research · Ophthalmology
American journal of ophthalmology · 14h
Cohort studyAmerican journal of ophthalmology · 2026

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco, Fangming Jin, Ali G Hamedani, Brian L VanderBeek
Read paper
OphthalmologyCohort study

Nucleic acid synthesis inhibitors/S1P modulators linked to much lower uveitis risk in multiple sclerosis

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco … Brian L VanderBeek
American journal of ophthalmology · 2026
Background

Whether disease-modifying therapies (disease-modifying therapies) for multiple sclerosis alter this risk is unknown.

Purpose

Multiple sclerosis (multiple sclerosis) is associated with an increased risk of noninfectious uveitis (noninfectious uveitis).

Methods

Adults with multiple sclerosis, defined by ≥3 diagnosis codes on separate dates, who received ≥1 disease-modifying therapies prescription and had ≥2 years of prior enrollment.

n = 43,501 patients
Results

risk of new eye inflammation was far lower than with a comparison multiple sclerosis drug

AHR by subgroup · 95% CI
null = 1
nucleic acid synthesis inhibitors/S1P
0.14
fumarates
0.51
anti-CD20
0.66
interferons
0.67
but not natalizumab
0.87
More results

Sensitivity analysis confirmed findings for fumarates (aHR 0.56, 95% CI: 0.38-0.82) and nucleic acid synthesis inhibitors/S1P modulators (aHR 0.16, 95% CI: 0.08-0.33).

“
Conclusion · 1 of 2

Certain disease-modifying therapies classes are associated with a protective effect for noninfectious uveitis in multiple sclerosis.

Conclusion · 2 of 2

If confirmed, these medications could be targeted for personalized multiple sclerosis treatment and potentially repurposed to treat noninfectious uveitis in other patient populations.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment